Michelle Cassara, MD
Endocrinology, Diabetes & Metabolism · Arvada, CONPI 1518092972
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $126,834 of the $141,472 with a category attached, or 89.7%. Novo Nordisk accounts for 94.2% of it on its own, with 24 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 263 payments — averaging $537.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$133K
- Sanofi-aventis U.S. LLC$6K
- Medtronic$665
- Lilly USA, LLC$241
- BETA Bionics, Inc.$199
- Tandem Diabetes Care, Inc.$178
- plus $1K from 19 others
What the payments were for
- Consulting fees$1,1251%
- Speaking & faculty fees$126,83490%
- Travel & lodging$7,4885%
- Food & beverage$6,0134%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 159 | $133,303 |
| Sanofi-aventis U.S. LLC | 14 | $5,596 |
| Medtronic(2 entities) | 17 | $665 |
| Lilly USA, LLC | 14 | $241 |
| BETA Bionics, Inc. | 3 | $199 |
| Tandem Diabetes Care, Inc. | 8 | $178 |
| Madrigal Pharmaceuticals | 2 | $161 |
| Dexcom, Inc. | 7 | $145 |
| Ascendis Pharma Endocrinology Inc | 2 | $140 |
| Insulet Corporation | 5 | $114 |
| AstraZeneca(2 entities) | 5 | $111 |
| Abbott | 5 | $104 |
| Mannkind Corporation | 3 | $97 |
| AbbVie | 4 | $91 |
| Cequr Corporation | 3 | $74 |
| Johnson & Johnson | 2 | $40 |
| Lifescan, Inc. | 1 | $38 |
| Ascensia Diabetes Care US Inc. | 2 | $31 |
| Radius Health, Inc. | 1 | $28 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| Amgen | 1 | $21 |
| Antares Pharma, Inc. | 1 | $17 |
| Sequel Med Tech, LLC | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$74,605
- RYBELSUS$31,806
- Tresiba$11,564
- SOLIQUA 100/33$3,325
- TOUJEO$2,142
- iLet Bionic Pancreas$474
- REZDIFFRA$135
- Yorvipath$121
- Wegovy$105
How this compares
$141,472 in reported general payments places this provider in the 95th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
See all endocrinology, diabetes & metabolism providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 155 | $244,002 |
| MounjaroTirzepatide | 153 | $174,374 |
| TrulicityDulaglutide | 79 | $108,790 |
| JardianceEmpagliflozin | 73 | $103,850 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 27 | $79,118 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $64,990 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $49,327 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 23 | $44,685 |
| InvokanaCanagliflozin | 24 | $34,743 |
| FarxigaDapagliflozin Propanediol | 35 | $33,565 |
| HumalogInsulin Lispro | 66 | $26,934 |
| SynthroidLevothyroxine Sodium | 213 | $22,732 |
| OmnitropeSomatropin | 11 | $22,629 |
| Humalog Kwikpen U-100Insulin Lispro | 60 | $20,716 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $20,026 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $241 | $311,477309 claims |
| Novo NordiskOzempic, Novolog, Tresiba | $133,303 | $264,550197 claims |
| Johnson & JohnsonInvokana | $40 | $34,74324 claims |
| AstraZenecaFarxiga | $111 | $33,56535 claims |
| AbbVieSynthroid, Armour Thyroid | $91 | $26,263236 claims |
| Sanofi-aventis U.S. LLCLantus | $5,596 | $6,30223 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $12 | $5,322514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
Other endocrinology, diabetes & metabolism in Arvada
- Irinel StanciuArvada$104K
- Leigh PerreaultBoulder$1.7M
- Satish GargAurora$347K
- Viralkumar ShahAurora$256K
- Neda RasouliAurora$188K
- Halis AkturkAurora$109K
- Robert EckelAurora$66K
- Marc Andre CornierAurora$62K
- Jane ReuschAurora$59K
- James FalkoAurora$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.